Drug Profile
E 6201
Alternative Names: E-6201; MEK-1/MEKK-1 Inhibitor - EisaiLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eisai Medical Research
- Developer Eisai Co Ltd; Mayo Clinic; National Cancer Institute (USA); Strategia Therapeutics; University of Arizona; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Lactones; Resorcinols
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; MAP kinase kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Phase I Brain metastases
- No development reported Solid tumours
- Discontinued Plaque psoriasis
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from preclinical studies in Solid tumours were presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 20 Sep 2022 Mayo Clinic initiates enrolment in a phase I trial for Brain metastases (Second-line therapy or greater, Combination therapy) in USA (NCT05388877)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Brain metastases (Second-line therapy or greater, Monotherapy) in USA (IV, Injection)